Olema Pharmaceuticals (OLMA) stock price is $7.25, up 1.97% on the day, as of Oct 20, 2026. It has a market cap of $756.24Mn, and is classified in the Pharmaceuticals industry (Healthcare sector).
Enterprise Value
Margins
P/FCF
Key Stats
Market Cap756.24 Mn
P/E-3.70
Div. Yield0.00
Total Debt (Qtr)3.00 Mn
Add ratio to table…
About
Olema Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on the discovery development and commercialization of next generation targeted therapies for breast cancer and beyond. The company leverages its deep understanding of endocrine driven cancers nuclear receptors and mechanisms of acquired resistance to build a pipeline of novel small molecule therapeutics. Its lead product candidate palazestrant is an oral available small molecule that functions…
Olema Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on the discovery development and commercialization of next generation targeted therapies for breast cancer and beyond. The company leverages its deep understanding of endocrine driven cancers nuclear receptors and mechanisms of acquired resistance to build a pipeline of novel small molecule therapeutics. Its lead product candidate palazestrant is an oral available small molecule that functions as both a complete estrogen receptor antagonist and a selective estrogen receptor degrader. Olema is advancing palazestrant through late stage clinical development both as a monotherapy and in combination with other targeted agents. A second product candidate OP-3136 targets the epigenetic enzyme KAT6 and is currently in early phase clinical testing. The company owns worldwide development and commercialization rights to both candidates.
Olema Pharmaceuticals, Inc. does not yet generate revenue from product sales because none of its candidates have received marketing approval. The company's current revenue streams consist of upfront license fees milestone payments and research funding obtained through collaboration agreements with pharmaceutical partners. For example Olema has received an upfront payment and milestone payments from its licensing agreement with Aurigene Oncology for the KAT6 inhibitor program. Additionally the company benefits from clinical trial collaborations with Novartis and Pfizer which provide investigational drug supply at no cost and may trigger further milestone payments upon achievement of predefined development goals. Olema also pursues non dilutive financing through private placements and public offerings to support its research and development activities. Upon eventual regulatory approval and commercial launch of palazestrant or OP-3136 the company expects to generate product sales revenue from hospitals clinics and outpatient treatment centers.
Olema Pharmaceuticals, Inc. positions itself as an innovator in the endocrine therapy space for estrogen receptor positive breast cancer. The company differentiates its lead candidate palazestrant by combining complete estrogen receptor antagonism with potent receptor degradation in an oral formulation a profile that addresses limitations of existing therapies such as fulvestrant aromatase inhibitors and tamoxifen. Competitors in the estrogen receptor targeted arena include AstraZeneca with its drug camizestrant Roche with giredestrant Eli Lilly with imlunestrant Arvinas in partnership with Pfizer with vepdegestrant and Stemline Therapeutics with elacestrant. For its KAT6 program Olema faces competition from Pfizer's investigational KAT6 inhibitor Stemline Therapeutics MEN2312 and BeOne Medicines investigational KAT6 inhibitor. Olema's competitive advantages stem from its deep scientific expertise in nuclear receptor biology its ability to generate oral small molecules with favorable pharmacokinetics and its strategy of retaining full worldwide development and commercialization rights to its product candidates. The company also leverages strategic collaborations with major pharmaceutical firms to access complementary agents and share development costs while maintaining control over its intellectual property.
Olema Pharmaceuticals, Inc. serves patients with estrogen receptor positive breast cancer and other solid tumor indications through its therapeutic candidates. The company's primary customers are hospitals oncology clinics and outpatient treatment centers that would administer its approved drugs to eligible patients. In addition Olema works closely with pharmaceutical partners such as Novartis Pharma AG Pfizer Inc. and Aurigene Oncology to conduct clinical trials and develop combination regimens. These collaborations provide access to investigational agents and expertise while allowing Olema to retain rights to its own molecules. The company also engages with academic research institutions and patient advocacy groups to gather clinical insights and support trial enrollment.
Sector:HealthcareSector rationaleOlema Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted therapies for breast cancer, specifically small molecule therapeutics like palazestrant and OP-3136. Its revenue model consists of license fees and milestone payments from pharmaceutical partners, with future revenue expected from the sale of drugs to hospitals and oncology clinics.Industry:PharmaceuticalsPharmaceuticalsPrimaryOlema Pharmaceuticals is a clinical-stage company developing novel small molecule therapeutics, such as palazestrant and OP-3136, for breast cancer. Its business model focuses on the discovery, development, and eventual commercialization of branded prescription drugs.Classified using BQ-MICSCIK: 0001750284
Bull & bear
Investment Thesis
▲ Bull case
The market is potentially overreacting to the negative news surrounding Olema Pharmaceuticals' oral SERD candidate based on the Roche trial failure, as this single data point may not fully capture the differentiated mechanism or clinical profile of Olema's own compound, which could demonstrate superior efficacy or safety in specific patient subgroups not addressed in the Roche study; furthermore, the company's pipeline includes earlier-stage assets targeting resistant forms of breast cancer that could unlock value through strategic partnerships or milestone payments, particularly if preclinical data shows promise in overcoming common resistance mechanisms seen with current endocrine therapies, and the recent stock decline may have created an attractive entry point for long-term investors who believe in the enduring need for oral SERDs in breast cancer treatment despite near-term setbacks.
Olema Pharmaceuticals may benefit from underappreciated tailwinds in the oncology space, including increasing regulatory flexibility for accelerated approvals based on biomarker-driven endpoints and growing payer interest in oral therapies that reduce healthcare system burden compared to intravenous alternatives, which could enhance commercial viability if the company's drug demonstrates non-inferiority or advantages in patient adherence and quality of life; additionally, the lack of detailed commentary from management during the recent downturn does not necessarily indicate weakness but could reflect a strategic focus on executing clinical milestones rather than engaging with short-term market noise, allowing the company to advance its programs without distraction, and any future positive clinical update—especially in a niche indication—could trigger a meaningful re-rating given the current depressed valuation and high short interest potentially setting up for a short-covering rally.
The market is potentially overreacting to the negative news surrounding Olema Pharmaceuticals' oral SERD candidate based on the Roche trial failure, as this single data point may not fully capture the differentiated mechanism or clinical profile of Olema's own compound, which could demonstrate superior efficacy or safety in specific patient subgroups not addressed in the Roche study; furthermore, the company's pipeline includes earlier-stage assets targeting resistant forms of breast cancer that could unlock value through strategic partnerships or milestone payments, particularly if preclinical data shows promise in overcoming common resistance mechanisms seen with current endocrine therapies, and the recent stock decline may have created an attractive entry point for long-term investors who believe in the enduring need for oral SERDs in breast cancer treatment despite near-term setbacks.
Olema Pharmaceuticals may benefit from underappreciated tailwinds in the oncology space, including increasing regulatory flexibility for accelerated approvals based on biomarker-driven endpoints and growing payer interest in oral therapies that reduce healthcare system burden compared to intravenous alternatives, which could enhance commercial viability if the company's drug demonstrates non-inferiority or advantages in patient adherence and quality of life; additionally, the lack of detailed commentary from management during the recent downturn does not necessarily indicate weakness but could reflect a strategic focus on executing clinical milestones rather than engaging with short-term market noise, allowing the company to advance its programs without distraction, and any future positive clinical update—especially in a niche indication—could trigger a meaningful re-rating given the current depressed valuation and high short interest potentially setting up for a short-covering rally.
Olema Pharmaceuticals faces significant near-term headwinds as the failure of Roche's oral SERD trial raises credible concerns about the class-wide viability of oral selective estrogen receptor degraders in front-line breast cancer, suggesting that biological or pharmacokinetic challenges—such as insufficient target engagement, rapid metabolism, or compensatory resistance pathways—may undermine the therapeutic hypothesis underlying Olema's own candidate, and if similar mechanisms are at play, the company's clinical prospects could be substantially diminished regardless of minor structural differences, making it difficult to justify current valuations based on unproven differentiation.
The securities law investigation announced by DJS Law Group introduces material legal and reputational risk, as allegations of misleading statements or inadequate disclosures related to competitive trial outcomes could result in costly litigation, settlements, or regulatory scrutiny, diverting management focus and financial resources from core R&D activities while potentially eroding investor trust and triggering further downward pressure on the stock, especially if internal communications reveal prior awareness of risks that were not adequately disclosed, and even in the absence of proven wrongdoing, the mere existence of an active investigation tends to increase volatility and deter institutional investment until resolution, compounding challenges in raising capital at favorable terms should additional funding be needed to advance clinical programs.
Olema Pharmaceuticals faces significant near-term headwinds as the failure of Roche's oral SERD trial raises credible concerns about the class-wide viability of oral selective estrogen receptor degraders in front-line breast cancer, suggesting that biological or pharmacokinetic challenges—such as insufficient target engagement, rapid metabolism, or compensatory resistance pathways—may undermine the therapeutic hypothesis underlying Olema's own candidate, and if similar mechanisms are at play, the company's clinical prospects could be substantially diminished regardless of minor structural differences, making it difficult to justify current valuations based on unproven differentiation.
The securities law investigation announced by DJS Law Group introduces material legal and reputational risk, as allegations of misleading statements or inadequate disclosures related to competitive trial outcomes could result in costly litigation, settlements, or regulatory scrutiny, diverting management focus and financial resources from core R&D activities while potentially eroding investor trust and triggering further downward pressure on the stock, especially if internal communications reveal prior awareness of risks that were not adequately disclosed, and even in the absence of proven wrongdoing, the mere existence of an active investigation tends to increase volatility and deter institutional investment until resolution, compounding challenges in raising capital at favorable terms should additional funding be needed to advance clinical programs.